Monopar Therapeutics
MNPR
6 hedge funds and large institutions have $403K invested in Monopar Therapeutics in 2020 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
20% more funds holding
Funds holding: 5 → 6 (+1)
0.03% more ownership
Funds ownership: 0.11% → 0.14% (+0.03%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
5% less capital invested
Capital invested by funds: $424K → $403K (-$21K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$96.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$30.4K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$97 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.98K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Northern Trust
Chicago,
Illinois
| $347K | +$96.9K | +2,999 | +30% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $25K | +$30.4K | +940 | New |
|
3
Morgan Stanley
New York
| $17K | – | – | – |
|
|
4
BlackRock
New York
| $14K | -$5.98K | -185 | -25% |
|
|
5
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$1K | -34 | Closed |
|
|
6
Wells Fargo
San Francisco,
California
| – | +$97 | +3 | New |
|
MNPR Hedge Fund Activity: Q3 2020 in Review
6 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q3 2020, worth a combined $403K — down 5% from $424K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new MNPR positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Northern Trust, adding an estimated $96.9K. The largest seller was BlackRock, cutting an estimated $5.98K.
- 6 institutional investors held Monopar Therapeutics (MNPR) as of Q3 2020, up from 5 in Q2 2020.
- Funds reported $403K of Monopar Therapeutics stock for Q3 2020, down 5% quarter-over-quarter.
- 2 funds opened new Monopar Therapeutics positions in Q3 2020 and 1 closed out, a net change of +1 holder.
- The largest Monopar Therapeutics buyer in Q3 2020 was Northern Trust, an estimated $96.9K added.
- The largest Monopar Therapeutics seller in Q3 2020 was BlackRock, an estimated $5.98K sold.
Based on aggregated 13F filings for Q3 2020.